Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 9/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | CCR2 | P41597 | 1/20 | 0.58 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7419541 | 0.98 | CXCR4 (0.59) | CXCR4SIGMAR1MEN1CHRM2CHRM1 | |
| SCHEMBL538314 | 0.93 | SIGMAR1 (0.66) | CXCR4SIGMAR1KMT2ATDP1CYP2A13 | |
| SCHEMBL7428156 | 0.93 | SIGMAR1 (0.66) | CXCR4SIGMAR1KMT2ATDP1CYP2A13 | |
| Hydrochloric Acid SCHEMBL2925660 | 0.92 | LMNA (0.65) | CXCR4SIGMAR1KMT2ACYP2A13KDM4E | |
| Hydrochloric Acid SCHEMBL7416879 | 0.92 | LMNA (0.65) | CXCR4SIGMAR1KMT2ACYP2A13KDM4E | |
| SCHEMBL23851311 | 0.84 | SIGMAR1 (0.72) | CXCR4SIGMAR1KMT2ATDP1CYP2A13 | |
| SCHEMBL9417737 | 0.84 | SIGMAR1 (0.72) | CXCR4SIGMAR1KMT2ACYP2A13KDM4E | |
| SCHEMBL12469301 | 0.83 | CHRM1 (0.55) | CXCR4SIGMAR1CHRM1CYP2A13KDM4E | |
| SCHEMBL30077068 | 0.83 | CHRM1 (0.55) | CXCR4SIGMAR1CHRM1CYP2A13KDM4E | |
| SCHEMBL5738303 | 0.83 | ALDH1A1 (0.73) | CXCR4SIGMAR1KMT2ACYP2A13KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | CXCR4 456/4885SIGMAR1 598/4885MEN1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.